|
|
|
|
|
|
Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenes
Alberto Acedo, David J Sanz, Mercedes Duran, Mar Infante, Lucia Perez-Cabornero, Cristina Miner, Eladio A Velasco Breast Cancer Research 2012, 14:R87 (25 May 2012)
Abstract | Provisional PDF
|
|
|
|
Loss of plakoglobin promotes decreased cell-cell contact, increased invasion and breast cancer cell dissemination in vivo
Ingunn Holen, Jacob Whitworth, Faith Nutter, Alyson Evans, Hannah K Brown, Diane V Lefley, Ivana Barbaric, Mark Jones, Penelope D Ottewell Breast Cancer Research 2012, 14:R86 (25 May 2012)
Abstract | Provisional PDF
|
|
|
|
JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer
Yi Fang Lee, Lance DAVID Miller, Xiu BIN Chan, Michael A Black, Brendan Pang, Chee WEE Ong, Manuel Salto-Tellez, Edison T Liu, Kartiki V Desai Breast Cancer Research 2012, 14:R85 (23 May 2012)
Abstract | Provisional PDF
|
|
|
|
CD44 enhances invasion of basal-like breast cancer cells by up-regulating serine protease and collagen-degrading enzymatic expression and activity
Nicola Montgomery, Ashleigh Hill, Suzanne McFarlane, Jessica Neisen, Anthony O'Grady, Susie Conlon, Karin Jirstrom, Elaine W Kay, David Waugh Breast Cancer Research 2012, 14:R84 (23 May 2012)
Abstract | Provisional PDF
|
|
|
|
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy
Abigail S Caudle, Tse-Kuan Yu, Susan L Tucker, Isabelle Bedrosian, Jennifer K Litton, Ana M Gonzalez-Angulo, Karen Hoffman, Funda Meric-Bernstam, Kelly K Hunt, Thomas Buchholz, Elizabeth A Mittendorf Breast Cancer Research 2012, 14:R83 (23 May 2012)
Abstract | Provisional PDF
|
|
|
|
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy
Laura S Dominici, Elizabeth A Mittendorf, Xuemei Wang, Jun Liu, Henry M Kuerer, Kelly K Hunt, Abenaa Brewster, Gildy V Babiera, Thomas A Buchholz, Funda Meric-Bernstam, Isabelle Bedrosian Breast Cancer Research 2012, 14:R82 (23 May 2012)
Abstract | Provisional PDF
|
|
|
|
Die and let live: harnessing BikDD to combat breast cancer stem cells
Mario Giuliano, Meghana V Trivedi, Rachel Schiff Breast Cancer Research 2012, 14:310 (23 May 2012)
Abstract | Full text | PDF
|
|
|
|
Bone marrow-derived, alternatively-activated macrophages enhance solid tumor growth and lung metastasis of mammary carcinoma cells in a Balb/C mouse orthotopic model
Han Jin Cho, Jae In Jung, Do Young Lim, Gyoo Taik Kwon, Song Her, Jong Hoon Park, Jung Han Yoon Park Breast Cancer Research 2012, 14:R81 (22 May 2012)
Abstract | Provisional PDF
| PubMed
|
|
|
|
MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis
Chang Hui, Fu Yujie, Yuan Lijia, Yi Long, Xu Hongxia, Zhou Yong, Zhu Jundong, Zhang Qianyong, Mi Mantian Breast Cancer Research 2012, 14:R80 (22 May 2012)
Abstract | Provisional PDF
| PubMed
|
|
|
|
Targeting triple-negative breast cancer cells with the HDAC inhibitor Panobinostat
Chandra R Tate, Lyndsay V Rhodes, H CHRIS Segar, Jennifer L Driver, F NELL Pounder, Matthew E Burow, Bridgette M Collins-Burow Breast Cancer Research 2012, 14:R79 (21 May 2012)
Abstract | Provisional PDF
| PubMed
|
Editor’s summary
Panobinostat is able to selectively target triple negative breast cancer (TNBC) cells by inducing hyperacetylation and cell cycle arrest at G2/M; partially reversing the morphological changes characteristic of breast cancer cells.
|
|
|
|
Back to the embryonic stage: Nodal as a biomarker for breast cancer progression
Menashe Bar-Eli Breast Cancer Research 2012, 14:105 (21 May 2012)
Abstract | Provisional PDF
|
|
|
|
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
Marion T Weigel, Zara Ghazoui, Anita K Dunbier, Sunil Pancholi, Mitch Dowsett, Lesley-Ann Martin Breast Cancer Research 2012, 14:R78 (18 May 2012)
Abstract | Provisional PDF
| PubMed
|
|
|
|
Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development
Martin A Rivas, Leandro Venturutti, Yi-Wen Huang, Roxana Schillaci, Tim Huang, Patricia V Elizalde Breast Cancer Research 2012, 14:R77 (14 May 2012)
Abstract | Provisional PDF
| PubMed
|
|
|
|
Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study
Rebecca Ritte, Annekatrin Lukanova, Franco Berrino, Laure Dossus, Anne Tjønneland, Anja Olsen, Thure Overvad, Kim Overvad, Françoise Clavel-Chapelon, Agnès Fournier, Guy Fagherazzi, Sabine Rohrmann, Birgit Teucher, Heiner Boeing, Krasimira Aleksandrova, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Domenico Palli, Sabina Sieri, Salvatore Panico, Rosario Tumino, Paolo Vineis, José Quirós, Genevieve Buckland, Maria-José Sánchez, Pilar Amiano, María-Dolores Chirlaque, Eva Ardanaz, Malin Sund, Per Lenner, Bas Bueno-de-Mesquita, Carla H van Gils, Petra HM Peeters et al.
Breast Cancer Research 2012, 14:R76 (14 May 2012)
Abstract | Provisional PDF
| PubMed
|
|
|
|
Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer
Luigi Strizzi, Katharine M Hardy, Naira V Margaryan, David W Hillman, Elisabeth A Seftor, Beiyun Chen, Xochiquetzal J Geiger, E Thompson, Wilma L Lingle, Cathy A Andorfer, Edith A Perez, Mary JC Hendrix Breast Cancer Research 2012, 14:R75 (11 May 2012)
Abstract | Provisional PDF
| PubMed | Cited on BioMed Central
|
Editor’s summary
The embryonic morphogen Nodal is associated with advanced stage invasive human breast cancer, and may have a role as both a prognostic biomarker and a therapeutic target.
|
|
|
|
Estrogen-related receptor alpha: an orphan finds a family
Aleksandra M Ochnik, Douglas Yee Breast Cancer Research 2012, 14:309 (10 May 2012)
Abstract | Full text | PDF | PubMed
|
|
|
|
Crk adaptor proteins act as key signaling integrators for breast tumorigenesis
Kelly E Fathers, Emily S Bell, Charles V Rajadurai, Sean Cory, Hong Zhao, Anna Mourskaia, Dongmei Zuo, Jason Madore, Anie Monast, Anne-Marie Mes-Masson, Andree-Anne Grosset, Louis Gaboury, Michael Hallett, Peter Siegel, Morag Park Breast Cancer Research 2012, 14:R74 (8 May 2012)
Abstract | Provisional PDF
| PubMed
|
|
|
|
Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer
Xiao Wu, Zhengmao Zhu, Weidong Li, Xiaoying Fu, Dan Su, Liya Fu, Zhiqian Zhang, Ang Luo, Xiaodong Sun, Li Fu, Jin-Tang Dong Breast Cancer Research 2012, 14:R73 (8 May 2012)
Abstract | Provisional PDF
| PubMed
|
|
|
|
CENP-A, an essential centromere protein, is a prognostic marker for relapse
in estrogen receptor-positive breast cancer
Susan L McGovern, Yuan Qi, Lajos Pusztai, William F Symmans, Thomas A Buchholz Breast Cancer Research 2012, 14:R72 (4 May 2012)
Abstract | Provisional PDF
| PubMed
|
Editor’s summary
The essential centromere protein, CENP-A, is a strong prognostic marker for distant relapse in estrogen-receptor positive breast cancer not treated with systemic therapy, and may contribute to disease progression.
|
|
|
|
Biomarkers characterization of circulating tumour cells in breast cancer patients
Rosa Nadal, Ana Fernandez, Pedro Sanchez-Rovira, Marta Salido, María Rodríguez, José García-Puche, Marta Macià, Josep Corominas, Miguel Delgado-Rodriguez, Lucas Gonzalez, Joan Albanell, Mónica Fernández, Francesc Solé, José Lorente, María Serrano Breast Cancer Research 2012, 14:R71 (3 May 2012)
Abstract | Provisional PDF
| PubMed
|
|
|
|
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
Lynnette Fernández-Cuesta, Catherine Oakman, Priscila Falagan-Lotsch, Ke-seay Smoth, Emmanuel Quinaux, Marc Buyse, M Dolci, Evandro Azambuja, Pierre Hainaut, Patrizia Dell'Orto, Denis Larsimont, Prudence A Francis, John Crown, Martine Piccart-Gebhart, Giuseppe Viale, Angelo Leo, Magali Olivier Breast Cancer Research 2012, 14:R70 (2 May 2012)
Abstract | Provisional PDF
| PubMed
|
|
|
|
Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term
Rachel C Jankowitz, Adam M Brufsky Breast Cancer Research 2012, 14:308 (30 April 2012)
Abstract | Full text | PDF | PubMed
|
|
|
|
Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers
Max Yan, Huiling Xu, Nic Waddell, Kristy Shield-Artin, Izhak Haviv, kConFab authors, Michael J McKay, Stephen B Fox Breast Cancer Research 2012, 14:R69 (26 April 2012)
Abstract | Provisional PDF
| PubMed
|
|
|
|
CIP2A is a target of bortezomib in human triple negative breast cancer cells
Ling-Ming Tseng, Chun-Yu Liu, Kung-Chi Chang, Pei-Yi Chu, Chung-Wai Shiau, Kuen-Feng Chen Breast Cancer Research 2012, 14:R68 (26 April 2012)
Abstract | Provisional PDF
| PubMed
|
|
|
|
PTHrP and breast cancer: more than hypercalcemia and bone metastases
Kata Boras-Granic, John J Wysolmerski Breast Cancer Research 2012, 14:307 (25 April 2012)
Abstract | Full text | PDF | PubMed
|
